The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cells displayed weak to moderate cytoplasmic staining. A few malignant melanomas were strongly stained. Most malignant gliomas were negative.
Most tumors showed weak positivity or were negative. Malignant melanomas displayed moderate to strong cytoplasmic immunoreactivity while for example renal and ovarian cancers showed moderate staining in several cases.
Weak to moderate cytoplasmic immunoreactivity, often with a granular pattern was observed in most malignancies. Several malignant gliomas, lymphomas, squamous and basal cell carcinomas, stomach, urothelial and pancreatic cancers were negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
